Dr. Ashley Wivel is an Executive Director in Global Clinical Safety and Pharmacovigilance at Merck where she supports both Vaccine and Infectious Disease products. She has 10 years of experience in the Pharmaceutical Industry with expertise in Pharmacovigilance, Risk Management, and Clinical Effectiveness Research. Ashley joined Merck in 2015 to support the accelerated development of an Ebola vaccine candidate. Prior to Merck, she worked as a Safety Development Leader in the Global Clinical Safety and Pharmacovigilance group at GlaxoSmithKline where she supported a range of therapeutic areas including rare diseases, cardiovascular, metabolic, oncology, and urology. Ashley’s clinical background is as an Emergency Physician, and she currently holds an appointment as a Clinical Associate at the University of Pennsylvania where she continues to teach physicians-in-training.